CHA Bio & Diostech 
Welcome,         Profile    Billing    Logout  
 4 Products   0 Diseases  4 Products   7 Trials   56 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ASP7317 / Octapharma, Astellas
NCT03178149: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Recruiting
1
42
US
ASP7317, tacrolimus, FK506, Prograf®, trimethoprim-sulfamethoxazole, TMP/SMX, Acyclovir, Nystatin
Astellas Institute for Regenerative Medicine
Age-Related Macular Degeneration
06/26
06/26
CB-AC-02 / CHA Bio & Diostech
NCT02899091: Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease

Active, not recruiting
1/2
24
RoW
CB-AC-02, Placebo
CHABiotech CO., Ltd
Alzheimer's Disease
12/24
12/24
CBT101 / CHA Bio & Diostech
NCT04557306: Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer

Completed
1
6
RoW
CBT101 cells, every 2 weeks, CBT101 cells, every 4 weeks
CHABiotech CO., Ltd
Solid Tumor
10/21
10/21
CordSTEM-DD (Enhanced umbilical cord adherent stem cell therapy) / CHA Bio & Diostech
NCT04530071: Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain

Completed
1/2
36
RoW
CordSTEM-DD (0.7 x 10^7 cells), CordSTEM-DD (2.1 x 10^7 cells), Placebo
CHABiotech CO., Ltd, Seoul CRO Co., Ltd.
Chronic Low-back Pain, Disc Degeneration
04/23
04/23

Download Options